orforglipron vs semaglutide
updated
orforglipron (tier S) vs semaglutide (tier S): what each is, half-life and source counts side by side.
orforglipron · tier S
foundayo. the first non-peptide small-molecule oral GLP-1 receptor agonist. a once-daily pill, no injection, FDA-approved april 2026 for chronic weight management.
tier rationale
S-tier because orforglipron clears the S bar the same way the other GLP-1 drugs do: full phase-3 programs (ATTAIN-1 n=3,127, ATTAIN-2 n=1,613, plus the ACHIEVE diabetes trials) and an FDA approval, granted April 1, 2026 as Foundayo for chronic weight management. drug-tier human evidence is the S threshold and orforglipron meets it. it sits in S even though its top-dose weight loss (about 12.4%) is below tirzepatide's, because S is about evidence quality and approval status, not relative effect size. the structural story is the headline: it is the first non-peptide small-molecule oral GLP-1 receptor agonist, a manufacturing and access shift for the whole category. all efficacy numbers are attributed to Lilly's reported phase-3 results and the approved label.
semaglutide · tier S
A GLP-1 receptor agonist with current US injection and oral products for distinct labeled uses.
tier rationale
The S tier reflects large randomized trials showing weight-loss, cardiovascular, and kidney benefits in the studied populations, plus positive biopsy outcomes in a planned phase 3 liver-disease interim analysis.
at a glance
| orforglipron | semaglutide | |
|---|---|---|
| tier | S | S |
| category | weight loss | weight loss |
| sources | 2 | 16 |
| claims evaluated | 7 | n/a |
| half-life | supports once-daily oral dosing per the FDA-approved label; small-molecule oral absorption without the food/water restrictions of oral peptide GLP-1s | ~1 week |
| dosing data | yes | yes |
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.